Drug Trial Radar · NCT06130566
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
601
Actual
Start
Nov 8, 2023
Primary completion
Jul 23, 2025
Study completion Nov 13, 2025
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for SC injection compared with placebo in participants with moderate to severe AD aged 12 years and older. Study details include: At the end of the treatment period, participants will have an option to enter a separate study: the blinded extension study EFC17600 (ESTUARY). For participants not entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized double-blind period, and a 16-week safety follow-up. For participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized double-blind period. The total treatment duration will be up to 24 weeks. The total number of visits will be up to 10 visits (or 9 visits for those entering the blinded extension study EFC17600\] (ESTUARY).
Conditions
- Dermatitis Atopic
Interventions
AmlitelimabDrug
Injection solution SC injection
PlaceboDrug
Injection solution SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24Time frame: Week 24
- EU, EU reference countries, and Japan: Proportion of participants reaching 75% reduction from baseline in Eczema Area and Severity Index (EASI) score (EASI-75) at Week 24Time frame: Week 24
- US and US reference countries: Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24Time frame: Week 24
Locations
148 sites in 15 countries. Site status is shown where the registry gives one.
Scottsdale Clinical Trials- Site Number : 8401149
Scottsdale, Arizona
First OC Dermatology- Site Number : 8401025
Fountain Valley, California
Center for Dermatology Clinical Research- Site Number : 8401018
Fremont, California
Sunwise Clinical Research- Site Number : 8401022
Lafayette, California
Carbon Health - North Hollywood - NoHo West- Site Number : 8401218
North Hollywood, California
Northridge Clinical Trials - Northridge- Site Number : 8401080
Northridge, California
St Jude Clinical Research- Site Number : 8401287
Doral, Florida
Beth Israel Deaconess Medical Center - Fort Myers- Site Number : 8401286
Fort Myers, Florida
Direct Helpers Research Center- Site Number : 8401056
Hialeah, Florida
Encore Medical Research- Site Number : 8401030
Hollywood, Florida
Florida International Research Center- Site Number : 8401091
Miami, Florida
Miami Dermatology and Laser Research- Site Number : 8401086
Miami, Florida
Clinical Neuroscience Solutions - Orlando - South Delaney Avenue- Site Number : 8401035
Orlando, Florida
Cleaver Medical Group Dermatology- Site Number : 8401139
Cumming, Georgia
Skin Care Physicians of Georgia - Macon- Site Number : 8401034
Macon, Georgia
Javara Research - Thomasville- Site Number : 8401189
Thomasville, Georgia
Rophe Adult & Pediatric Medicine- Site Number : 8401289
Union City, Georgia
Skin Sciences- Site Number : 8401039
Louisville, Kentucky
MedPharmics - Covington- Site Number : 8401137
Covington, Louisiana
MedPharmics - Lafeyette- Site Number : 8401152
Lafayette, Louisiana
Massachusetts General Hospital- Site Number : 8401192
Boston, Massachusetts
Metro Boston Clinical Partners- Site Number : 8401128
Needham, Massachusetts
Revival Research - Doral- Site Number : 8401012
Dearborn, Michigan
Henry Ford Hospital- Site Number : 8401044
Detroit, Michigan
SKY Integrative Medical Center/SKYCRNG - Ridgeland- Site Number : 8401058
Ridgeland, Mississippi
MediSearch Clinical Trials- Site Number : 8401140
Saint Joseph, Missouri
Somnos Clinical Research- Site Number : 8401203
Lincoln, Nebraska
Universal Dermatology- Site Number : 8401224
Fairport, New York
Sadick Research Group - New York - Park Avenue- Site Number : 8401050
New York, New York
CHEAR Center- Site Number : 8401123
The Bronx, New York
Onsite Clinical Solutions - Charlotte - Blakeney Park Drive- Site Number : 8401124
Charlotte, North Carolina
Oregon Medical Research Center- Site Number : 8401017
Portland, Oregon
Vial Health - DermDox Dermatology- Site Number : 8401031
Camp Hill, Pennsylvania
Paddington Testing Company- Site Number : 8401041
Philadelphia, Pennsylvania
Clinical Research of Philadelphia- Site Number : 8401193
Philadelphia, Pennsylvania
Tribe Clinical Research - 525 Verdae Boulevard- Site Number : 8401225
Greenville, South Carolina
Dermatology Treatment and Research Center- Site Number : 8401164
Dallas, Texas
Skin Specialist of Addison- Site Number : 8401208
Dallas, Texas
Texas Dermatology and Laser Specialists- Site Number : 8401131
San Antonio, Texas
Stryde Research - Epiphany Dermatology- Site Number : 8401185
Southlake, Texas
Showing 40 of 148 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.